← Back to Search

Alkylating agents

Tafasitamab + Lenalidomide for Diffuse Large B-Cell Lymphoma (frontMIND Trial)

Phase 3
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization until the date of death from any cause (up to 62 months)
Awards & highlights
Pivotal Trial

Summary

This trial tests a new treatment combining an antibody, an immune-boosting drug, and standard chemotherapy for high-risk patients with newly diagnosed aggressive lymphoma. The goal is to see if this combination works better than standard chemotherapy alone. Rituximab, when combined with standard chemotherapy, has shown significant improvements in response rates and survival for patients with aggressive lymphoma.

Who is the study for?
This trial is for adults with untreated CD20-positive DLBCL, a type of lymphoma. They must be suitable for R-CHOP therapy and have an ECOG performance status of 0-2, meaning they are fully active or at least ambulatory. Participants need proper heart function and agree to contraception if applicable. Those with certain other cancers, CNS involvement by lymphoma, significant health issues, infections like TB, or prior anti-lymphoma treatment aren't eligible.
What is being tested?
The study tests the effectiveness and safety of adding tafasitamab plus lenalidomide to the standard R-CHOP regimen against R-CHOP alone in high-risk DLBCL patients. It's a phase 3 trial where participants are randomly assigned to either receive the new combination or placebo alongside their regular chemotherapy.
What are the potential side effects?
Potential side effects include reactions related to immune system activation such as infusion-related symptoms (fever, chills), blood cell count changes leading to increased infection risk or bleeding problems, fatigue from treatment burden on the body's resources, organ-specific inflammation due to immune response misdirection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization until the date of death from any cause (up to 62 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization until the date of death from any cause (up to 62 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PFS-INV
Secondary study objectives
Duration of Complete Response (CR) as assessed by the investigator
EFS at 3 years
EFS-INV
+7 more

Side effects data

From 2023 Phase 2 trial • 81 Patients • NCT02399085
64%
Any TEAE
49%
Neutropenia
37%
Diarrhoea
37%
Anaemia
30%
Cough
28%
Thrombocytopenia
26%
Asthenia
25%
Oedema peripheral
22%
Pyrexia
22%
Decreased appetite
20%
Back pain
19%
Hypokalaemia
19%
Constipation
16%
Fatigue
15%
Vomiting
15%
Bronchitis
15%
Muscle spasms
15%
Nausea
12%
Leukopenia
12%
Urinary tract infection
12%
Dyspnoea
11%
Respiratory tract infection
11%
C-reactive protein increased
10%
Abdominal pain
10%
Nasopharyngitis
10%
Upper respiratory tract infection
10%
Pruritus
10%
Rash
10%
Pain in extremity
10%
Hypomagnesaemia
9%
Pneumonia
9%
Rhinitis
9%
Headache
9%
Paraesthesia
9%
Blood creatinine increased
9%
Hypertension
7%
Sinusitis
7%
Abdominal pain upper
7%
Mucosal inflammation
7%
Gastroenteritis
7%
Gamma-glutamyltransferase increased
7%
Anxiety
7%
Oropharyngeal pain
7%
Arthralgia
7%
Hypotension
6%
Sciatica
6%
Rash maculo-papular
6%
Febrile neutropenia
6%
Dysuria
6%
Blood alkaline phosphatase increased
6%
Hyperglycaemia
6%
Productive cough
6%
Lymphopenia
6%
Hypocalcaemia
6%
Hypogammaglobulinaemia
6%
Infusion related reaction
4%
COVID-19
4%
Pulmonary embolism
2%
Basal cell carcinoma
2%
Lower respiratory tract infection
2%
Squamous cell carcinoma
2%
Atrial fibrillation
2%
Cardiac failure congestive
1%
Transient ischaemic attack
1%
Cholecystitis
1%
Haematoma
1%
Prostate cancer
1%
Enterobacter bacteraemia
1%
Escherichia bacteraemia
1%
Febrile infection
1%
Influenza
1%
Klebsiella sepsis
1%
Bowen's disease
1%
Breast cancer
1%
Lung adenocarcinoma
1%
Myelodysplastic syndrome
1%
Intervertebral discitis
1%
Cardio-respiratory arrest
1%
Bronchopulmonary aspergillosis
1%
Cerebrovascular accident
1%
Cervicobrachial syndrome
1%
Transient global amnesia
1%
Sudden death
1%
COVID-19 pneumonia
1%
Gastroenteritis rotavirus
1%
Myeloproliferative neoplasm
1%
Cytomegalovirus infection
1%
Neutropenic sepsis
1%
Parainfluenzae virus infection
1%
Progressive multifocal leukoencephalopathy
1%
Respiratory syncytial virus infection
1%
Sepsis
1%
Soft tissue infection
1%
Streptococcal sepsis
1%
Urinary tract infection enterococcal
1%
Varicella zoster virus infection
1%
Lower limb fracture
1%
Wound complication
1%
Tumour flare
1%
Biliary colic
1%
Muscular weakness
1%
Agranulocytosis
1%
Cardiac failure
1%
Myocardial ischaemia
1%
Cognitive disorder
1%
Facial paralysis
1%
Chronic obstructive pulmonary disease
1%
Respiratory failure
1%
Arthritis
1%
Osteonecrosis
1%
Pathological fracture
1%
Femur fracture
1%
Renal failure
1%
Deep vein thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (MOR00208, Lenalidomide)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Tafasitamab plus lenalidomide in addition to R-CHOPExperimental Treatment7 Interventions
Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles: Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15. Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle
Group II: Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOPPlacebo Group7 Interventions
Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles: Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle Lenalidomide placebo: Days 1-10 of each 21-day cycle R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenalidomide
2005
Completed Phase 3
~2240
Rituximab
1999
Completed Phase 4
~2990
Cyclophosphamide
2010
Completed Phase 4
~2310
Tafasitamab
2016
Completed Phase 3
~630
Doxorubicin
2012
Completed Phase 3
~8030
Vincristine
2003
Completed Phase 4
~2970
Prednisone
2014
Completed Phase 4
~2500

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Tafasitamab is a monoclonal antibody that targets CD19 on B cells, leading to their destruction through immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. Lenalidomide modulates the immune response by enhancing T-cell and natural killer (NK) cell function, and inhibiting angiogenesis and cytokine release. These mechanisms are crucial for DLBCL patients as they directly target malignant B cells and enhance the body's immune response to fight the cancer, potentially leading to better treatment outcomes.

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
393 Previous Clinical Trials
62,945 Total Patients Enrolled
34 Trials studying Lymphoma
4,151 Patients Enrolled for Lymphoma
MorphoSys AGLead Sponsor
26 Previous Clinical Trials
5,697 Total Patients Enrolled
11 Trials studying Lymphoma
4,977 Patients Enrolled for Lymphoma
Incyte Medical DirectorStudy DirectorIncyte Corporation
3 Previous Clinical Trials
528 Total Patients Enrolled
2 Trials studying Lymphoma
503 Patients Enrolled for Lymphoma
Andrea Sporchia, MDStudy DirectorMorphoSys AG
Associate Director, Clinical DevelopmentStudy DirectorMorphoSys AG

Media Library

Cyclophosphamide (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT04824092 — Phase 3
Lymphoma Research Study Groups: Tafasitamab plus lenalidomide in addition to R-CHOP, Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP
Lymphoma Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT04824092 — Phase 3
Cyclophosphamide (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04824092 — Phase 3
~94 spots leftby Jun 2025